CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


AtorvastatinWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)


Name (Synonyms) Correlation
drug1254 Intravenous sedation Wiki 1.00
drug1213 Inhaled sedation Wiki 1.00

Correlated MeSH Terms (4)


Name (Synonyms) Correlation
D013577 Syndrome NIH 0.11
D055371 Acute Lung Injury NIH 0.10
D012127 Respiratory Distress Syndrome, Newborn NIH 0.10
D012128 Respiratory Distress Syndrome, Adult NIH 0.09

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 Prospective Randomized Open-label Trial of Atorvastatin as Adjunctive Treatment of COVID-19

Objective: To assess whether adjunctive therapy of COVID-19 infection with atorvastatin reduces the deterioration in hospitalized patients and improves clinical outcome.

NCT04380402 COVID-19 Drug: Atorvastatin

Primary Outcomes

Description: Proportion of patients in each arm that progress to severe or critical requiring ICU admission and/or emergency salvage therapy, or death, as described by WHO Ordinal Scale for Clinical Improvement scores 5-8 with higher being worse.

Measure: Proportion of patients that progress to severe or critical requiring ICU admission and/or emergency salvage therapy, or death

Time: 30 days

Secondary Outcomes

Description: Description of clinical status of patients in each arm based on WHO Ordinal Scale of Clinical Improvement on Day 7, scores 1-8 with higher being worse.

Measure: Overall score of patients in each arm on Day 7 based on WHO Ordinal Scale for Clinical Improvement

Time: 7 days

Description: Description of clinical status of patients in each arm based on WHO Ordinal Scale of Clinical Improvement on Day 30, scores 1-8 with higher being worse.

Measure: Overall score of patients in each arm on Day 30 based on WHO Ordinal Scale for Clinical Improvement

Time: 30 days

Description: Proportions of patients in each arm who are tested on Day 7 and have negative PCR

Measure: Proportions of patients in each arm who test negative for SARS-CoV-2 on Day 7

Time: 7 days


No related HPO nodes (Using clinical trials)